Moderna Beats Estimates on International Covid Shot Sales -- WSJ

Dow Jones05-01 22:24

By Xavier Martinez

Moderna reported a more than threefold jump in sales to $389 million for the first quarter, driven by international Covid vaccine sales under long-term government partnerships.

The Cambridge, Mass., drugmaker reported a net loss of $1.3 billion for the March quarter. Stripping out a roughly $900 million charge tied to a litigation settlement over Covid-shot technology, the adjusted loss was $465 million-better than what analysts had anticipated.

Shares rallied in premarket before opening slightly lower.

Moderna is waiting on a Food and Drug Administration decision by early August on whether to approve its first standalone flu shot, and expects late-stage results later this year from a personalized cancer vaccine for melanoma that could mark a new way to treat the disease.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

May 01, 2026 10:24 ET (14:24 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632164831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632164831","market":"other","top_or_hot":-1,"title":"Moderna Beats Estimates on International Covid Shot Sales -- WSJ","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Xavier Martinez \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> reported a more than threefold jump in sales to $389 million for the first quarter, driven by international Covid vaccine sales under long-term government partnerships. \n</p>\n<p>\n     The Cambridge, Mass., drugmaker reported a net loss of $1.3 billion for the March quarter. Stripping out a roughly $900 million charge tied to a litigation settlement over Covid-shot technology, the adjusted loss was $465 million-better than what analysts had anticipated. \n</p>\n<p>\n     Shares rallied in premarket before opening slightly lower. \n</p>\n<p>\n     Moderna is waiting on a Food and Drug Administration decision by early August on whether to approve its first standalone flu shot, and expects late-stage results later this year from a personalized cancer vaccine for melanoma that could mark a new way to treat the disease. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2026 10:24 ET (14:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Beats Estimates on International Covid Shot Sales -- WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Beats Estimates on International Covid Shot Sales -- WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-01 22:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Xavier Martinez \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> reported a more than threefold jump in sales to $389 million for the first quarter, driven by international Covid vaccine sales under long-term government partnerships. \n</p>\n<p>\n     The Cambridge, Mass., drugmaker reported a net loss of $1.3 billion for the March quarter. Stripping out a roughly $900 million charge tied to a litigation settlement over Covid-shot technology, the adjusted loss was $465 million-better than what analysts had anticipated. \n</p>\n<p>\n     Shares rallied in premarket before opening slightly lower. \n</p>\n<p>\n     Moderna is waiting on a Food and Drug Administration decision by early August on whether to approve its first standalone flu shot, and expects late-stage results later this year from a personalized cancer vaccine for melanoma that could mark a new way to treat the disease. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2026 10:24 ET (14:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632164831","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632164831","pubTimestamp":1777645440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Moderna reported a more than threefold jump in sales to $389 million for the first quarter, driven by international Covid vaccine sales under long-term government partnerships.The Cambridge, Mass., drugmaker reported a net loss of $1.3 billion for the March quarter. Stripping out a roughly $900 million charge tied to a litigation settlement over Covid-shot technology, the adjusted loss was $465 million-better than what analysts had anticipated.Shares rallied in premarket before opening slightly lower.Moderna is waiting on a Food and Drug Administration decision by early August on whether to approve its first standalone flu shot, and expects late-stage results later this year from a personalized cancer vaccine for melanoma that could mark a new way to treat the disease.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","MRNA":"Moderna, Inc.","BK4568":"美国抗疫概念","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BK4534":"瑞士信贷持仓","BK4588":"碎股","BK4548":"巴美列捷福持仓","MRNY":"MRNA期权收益策略ETF-YieldMax","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念"},"translate_title":"Moderna国际新冠疫苗销量超出预期——《华尔街日报》","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNY":0.6,"MRNA":0.9,"MRNX":0.6},"content_text":"By Xavier Martinez \n\n\nModerna reported a more than threefold jump in sales to $389 million for the first quarter, driven by international Covid vaccine sales under long-term government partnerships. \n\n\n     The Cambridge, Mass., drugmaker reported a net loss of $1.3 billion for the March quarter. Stripping out a roughly $900 million charge tied to a litigation settlement over Covid-shot technology, the adjusted loss was $465 million-better than what analysts had anticipated. \n\n\n     Shares rallied in premarket before opening slightly lower. \n\n\n     Moderna is waiting on a Food and Drug Administration decision by early August on whether to approve its first standalone flu shot, and expects late-stage results later this year from a personalized cancer vaccine for melanoma that could mark a new way to treat the disease. \n\n\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2026 10:24 ET (14:24 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632164831","isCrawlerRequest":true}